Dr Reddy's Labs unveils Venlafaxine ER tablets in US
Hyderabad: Drug maker, Dr. Reddy's Laboratories Ltd., has recently announced the launch of Venlafaxine ER Tablets.The product is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration (USFDA).Venlaxafine extended release tablets are a selective serotonin and...
Hyderabad: Drug maker, Dr. Reddy's Laboratories Ltd., has recently announced the launch of Venlafaxine ER Tablets.
The product is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150 mg and 225 mg, of Osmotica Pharmaceutical US LLC approved by the U.S. Food and Drug Administration (USFDA).
Venlaxafine extended release tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for major depressive disorder and social anxiety disorder.
The brand and generic had U.S. sales of approximately $51 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.
Dr. Reddy's Venlafaxine ER Tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
Read also: Dr Reddys launches Valsartan in US
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd